Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 4

ALNYLAM Form 4 June 10, 201	PHARMACEU	FICALS, 1	INC.								
FORN Check th	UNITED	STATES		RITIES A			NGE	COMMISSION		PPROVAL 3235-02	
if no long subject to Section 1 Form 4 o Form 5	ger STATEN 16. or	STATEMENT OF CHANGES IN BE SECURIT							Estimated burden hou	Expires:January 31, 2005Estimated average burden hours per response0.5	
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type I	Responses)										
1. Name and A Gros David	Person [*]	2. Issuer Name and Ticker or Trading Symbol				ng	5. Relationship of Reporting Person(s) to Issuer				
			ALNYLAM PHARMACEUTICALS, INC. [ALNY]					(Check all applicable)			
(Last) (First) (Middle) 300 THIRD STREET			3. Date of Earliest Transaction (Month/Day/Year) 06/08/2015			X_Officer (give title Other (specify below) below) SVP, Chief Business Officer					
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person 					
CAMBRID	GE, MA 02142							Form filed by Person	More than One R	eporting	
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivativ	e Secur	ities A	cquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8)	Disposed (Instr. 3,	d (A) or d of (D) 4 and 5 (A) or	j)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Pamindan Dan	ort on a senarata line	for each al	nes of see	Code V			Price	or indirectly			
Keminder: Kep	oort on a separate line	or each cl		unues bene	Pers infor requ	ons wh mation ired to ays a c	no res i cont respo	point to the colle ained in this form and unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities

Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Disposed of	Acquired (A) or Disposed of (D) (Instr. 3, 4, and		(Month/Day/Year)		(Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 129.97	06/08/2015		A	140,000		<u>(1)</u>	06/08/2025	Common Stock	140,000	

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Gros David-Alexandre C 300 THIRD STREET CAMBRIDGE, MA 02142			SVP, Chief Business Officer				
Signatures							

3

By: /s/ Michael P. Mason, Attorney-in-Fact For: David-Alexandre C. Gros	06/10/2015	
**Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of (1) the shares each successive three month period thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.